Revolution Medicines officer plans $802,650 sale

An officer of Revolution Medicines filed a Rule 144 notice to sell 3,939 RVMD shares from RSU vesting, after significant sales earlier in the past three months.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) has an officer, Jack Anders, filing a notice of proposed sale of common stock under Rule 144. The notice covers 3,939 shares of common stock, to be sold through E*TRADE Financial Corporation on or about September 15, 2026, with an indicated aggregate market value of $802,650.03.

The shares to be sold arise from RSU vesting from the issuer as compensation for services rendered. The filing also reports prior sales in the last three months: 20,000 shares of common stock on June 24, 2026 for $3,366,604.46 and 2,722 shares on June 16, 2026 for $424,956.46.

Key Figures

Shares proposed for sale: 3,939 shares Aggregate market value of proposed sale: $802,650.03 Planned sale date: September 15, 2026 +4 more

7 metrics

Shares proposed for sale 3,939 shares Common stock covered by the Rule 144 notice through E*TRADE

Aggregate market value of proposed sale $802,650.03 Reported value for 3,939 shares of common stock

Planned sale date September 15, 2026 Date associated with the proposed Rule 144 sale

Prior sale on June 24, 2026 20,000 shares; $3,366,604.46 Common stock sold during the preceding three months

Prior sale on June 16, 2026 2,722 shares; $424,956.46 Common stock sold during the preceding three months

Broker E*TRADE Financial Corporation Broker handling the proposed Rule 144 sale

Trading market NASDAQ Exchange where the common stock is listed

Key Terms

Rule 144, RSU vesting, services rendered, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU vesting financial

"Common Stock | 09/15/2026 | RSU vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

services rendered financial

"3939 | 09/15/2026 | Services rendered"

NASDAQ market

"214336418 | 09/15/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for RVMD disclose about upcoming share sales?

The Form 144 discloses that an officer, Jack Anders, intends to sell up to 3,939 shares of Revolution Medicines common stock through E*TRADE Financial Corporation on or about September 15, 2026, under Rule 144.

How many RVMD shares did the reporting person sell in the last three months?

The filing reports two sales: 20,000 shares of Revolution Medicines common stock on June 24, 2026 for $3,366,604.46 and 2,722 shares on June 16, 2026 for $424,956.46.

What is the source of the RVMD shares to be sold under this Form 144?

The 3,939 shares of Revolution Medicines common stock to be sold are reported as arising from RSU vesting from the issuer, received on September 15, 2026 as consideration for services rendered.

What is the aggregate market value of the RVMD shares covered by this Form 144?

The filing indicates an aggregate market value of $802,650.03 for the 3,939 shares of Revolution Medicines common stock proposed to be sold through E*TRADE Financial Corporation.

On which market are the RVMD shares in this Form 144 expected to trade?

The common stock covered by this Form 144 is listed for trading on NASDAQ, as specified in the securities information section of the filing.

Who is the person filing the Form 144 related to RVMD and what is their role?

The notice is filed for Jack Anders, identified as an officer of Revolution Medicines, Inc., for whose account the Rule 144 securities are to be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 06:05 PM EDT Accepted by SEC EDGAR 09/15/2026 - 06:05 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001800668
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Anders Jack
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	3939	802650.03	214336418	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/15/2026	RSU vesting	Issuer			3939	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jack Anders c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/24/2026	20000	3366604.46
Jack Anders c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2026	2722	424956.46

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/31/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jack Anders
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)